UNSPSC 51172116: Aminopromazine

This classification denotes an antispasmotic agent with the molecular formula C19H25N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S9SDD93U5U, chemically known as 1,2-propanediamine, n,n,n,n-tetramethyl-3-(10h-phenothiazin-10-yl)- but generally known as aminopromazine, which bears US NIH Compound Identifier 19392. Aminopromazine most often comes in base and fumarate forms. European Medicines Agency schedules Aminopromazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05445MIG.

UNSPSC 51172116 Aminopromazine, a Commodity code, covers pharmaceutical products procured by state and local government agencies for institutional and population health programs. Recent state and local solicitations under this code show a broader pattern than the specific drug name suggests: aminopromazine appears primarily in large-scale cooperative purchasing agreements for multi-source generic pharmaceuticals and in clinical testing and specimen collection services operated by criminal justice agencies. The issuing bodies include state departments (Texas Health and Human Services Commission), county corrections departments (Collin County Community Supervision and Corrections Department in Texas), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple jurisdictions including Oregon). These agencies procure aminopromazine and related pharmaceutical products as part of larger drug formularies for offender health management, employee health plans, and institutional pharmacy distribution networks.

Recent activity centers in Texas and Minnesota, with Collin County's RFP for Offender Specimen Collection and Drug Testing Services (posted July 9, 2026, due July 23, 2026) requesting drug testing panels that routinely screen for antipsychotic metabolites consistent with aminopromazine use in correctional populations. The estimated contract value is $600,000 over two years with renewal options through five years total. Separately, the Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers, with contract term commencing July 1, 2026 and covering state and local government facilities across participating jurisdictions. The Texas Health and Human Services Commission also issued RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs that could reshape pharmaceutical procurement channels for state agencies. Pricing in these procurements is typically competitive and quantity-driven, with pharmaceutical suppliers expected to maintain FDA compliance, cGMP certification, and Drug Supply Chain Security Act compliance.